Understanding Late-Onset Interstitial Lung Disease in Systemic Sclerosis: Implications for Clinical Practice and Trial Design.
作者信息
Volkmann Elizabeth R
机构信息
David Geffen School of Medicine, University of California, Los Angeles.
出版信息
Arthritis Rheumatol. 2025 Apr;77(4):380-382. doi: 10.1002/art.43053. Epub 2024 Dec 1.
Abstract
摘要
相似文献
1
Understanding Late-Onset Interstitial Lung Disease in Systemic Sclerosis: Implications for Clinical Practice and Trial Design.
Arthritis Rheumatol. 2025 Apr;77(4):380-382. doi: 10.1002/art.43053. Epub 2024 Dec 1.
2
Thoracic lymphadenopathy as possible predictor of the onset of interstitial lung disease in systemic sclerosis patients without lung involvement at baseline visit: A retrospective analysis.
J Scleroderma Relat Disord. 2020 Oct;5(3):210-218. doi: 10.1177/2397198320923545. Epub 2020 Jun 2.
3
Rationale for the evaluation of nintedanib as a treatment for systemic sclerosis-associated interstitial lung disease.
J Scleroderma Relat Disord. 2019 Oct;4(3):212-218. doi: 10.1177/2397198319841842. Epub 2019 Apr 21.
4
Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies.
Ann Am Thorac Soc. 2016 Nov;13(11):2045-2056. doi: 10.1513/AnnalsATS.201606-426FR.
5
Determining progression of scleroderma-related interstitial lung disease.
J Scleroderma Relat Disord. 2019 Feb;4(1):62-70. doi: 10.1177/2397198318816915. Epub 2018 Dec 17.
6
Patient-reported outcome measures in systemic sclerosis-related interstitial lung disease for clinical practice and clinical trials.
J Scleroderma Relat Disord. 2020 Mar;5(2 Suppl):48-60. doi: 10.1177/2397198320904178. Epub 2020 Mar 5.
7
Interstitial lung disease is associated with an increased risk of lung cancer in systemic sclerosis: Longitudinal data from the Canadian Scleroderma Research Group.
J Scleroderma Relat Disord. 2018 Oct;3(3):221-227. doi: 10.1177/2397198318766825. Epub 2018 Apr 10.
8
Design of CONQUEST, a novel, randomized, placebo-controlled, Phase 2b platform clinical trial to investigate new treatments for patients with early active systemic sclerosis with interstitial lung disease.
J Scleroderma Relat Disord. 2024 Nov 5:23971983241278079. doi: 10.1177/23971983241278079.
9
Physician-patient communication in the treatment of systemic sclerosis-associated interstitial lung disease: A narrative review and recommendations.
J Scleroderma Relat Disord. 2025 Mar 20:23971983251324803. doi: 10.1177/23971983251324803.
10
Pathogenesis of systemic sclerosis associated interstitial lung disease.
J Scleroderma Relat Disord. 2020 Mar;5(2 Suppl):6-16. doi: 10.1177/2397198320903867. Epub 2020 Mar 5.
本文引用的文献
1
Characterization of Incident Interstitial Lung Disease in Late Systemic Sclerosis.
Arthritis Rheumatol. 2025 Apr;77(4):450-457. doi: 10.1002/art.43051. Epub 2025 Jan 7.
2
2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases.
Arthritis Rheumatol. 2024 Aug;76(8):1201-1213. doi: 10.1002/art.42860. Epub 2024 Jul 8.
3
Enrichment Strategies for Systemic Sclerosis-Interstitial Lung Disease Trials.
Am J Respir Crit Care Med. 2024 May 1;209(9):1067-1068. doi: 10.1164/rccm.202401-0246ED.
4
Characteristics and disease course of untreated patients with interstitial lung disease associated with systemic sclerosis in a real-life two-centre cohort.
RMD Open. 2024 Jan 9;10(1):e003658. doi: 10.1136/rmdopen-2023-003658.
5
Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline.
Am J Respir Crit Care Med. 2024 Jan 15;209(2):137-152. doi: 10.1164/rccm.202306-1113ST.
6
Systemic sclerosis.
Lancet. 2023 Jan 28;401(10373):304-318. doi: 10.1016/S0140-6736(22)01692-0. Epub 2022 Nov 25.
7
Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and Research.
Chest. 2023 Mar;163(3):586-598. doi: 10.1016/j.chest.2022.09.044. Epub 2022 Oct 14.
8
Dyspnoea and cough in patients with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial.
Rheumatology (Oxford). 2022 Nov 2;61(11):4397-4408. doi: 10.1093/rheumatology/keac091.
9
Performance Characteristics of Pulmonary Function Tests for the Detection of Interstitial Lung Disease in Adults With Early Diffuse Cutaneous Systemic Sclerosis.
Arthritis Rheumatol. 2020 Nov;72(11):1892-1896. doi: 10.1002/art.41415. Epub 2020 Sep 22.
10
Role of imaging in progressive-fibrosing interstitial lung diseases.
Eur Respir Rev. 2018 Dec 21;27(150). doi: 10.1183/16000617.0073-2018. Print 2018 Dec 31.
Zotero 插件